Latest Ai Platforms News

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

Algorae Pharmaceuticals has independently validated its AI-driven drug combination platform, AlgoraeOS v1, confirming its ability to predict synergistic cancer drug pairs. The company has also launched an upgraded version, AlgoraeOS v2, poised to enhance drug discovery efforts.

Pathkey.AI Ltd has announced a pro rata non-renounceable rights issue to raise approximately $920,517, alongside a $2.5 million placement, aiming to fund enhancements to its AI platform and strategic expansion.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Straker Ltd’s H1 FY26 results reveal a strategic shift from legacy translation services to AI-driven specialised language models, anchored by a $28 million partnership with IBM. Despite a 15% revenue decline, the company maintains positive adjusted EBITDA and a strong balance sheet.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.

Icetana reveals its FY26 strategy focused on transforming Security Operations Centers with predictive, explainable, and autonomous AI, aiming to enhance threat detection and operational efficiency.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.

Nexion Group has finalized the sale of its Nexion Networks and Blue Sky Telecom subsidiaries, pivoting its focus towards AI-driven business intelligence through Fuse Forward.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Activeport Group Ltd has launched a new AI model routing platform that leverages its GPU orchestration expertise to deliver secure, sovereign AI hosting with hybrid cloud compatibility.